Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 10Breast 4Gastrointestinal 3Thoracic 2Sarcoma 2Lymphoid 2Gynecologic 2Genitourinary 2Dermatologic 2

Conditions

Melanoma 250Uveal Melanoma 29Neoplasm Metastasis 22Skin Neoplasms 17Brain Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Merkel Cell 10Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Triple Negative Breast Neoplasms 7Carcinoma, Hepatocellular 7Uterine Cervical Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Basal Cell 4Sarcoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2

Interventions

pembrolizumab 24Nivolumab 9atezolizumab 8Drug Therapy 6cemiplimab 5Immune Checkpoint Inhibitors 5fludarabine 4Radiotherapy 4Paclitaxel 4Interleukin-2 4Cyclophosphamide 4Docetaxel 3fludarabine phosphate 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Radiation 2Patient Reported Outcome Measures 2Oncolytic Virotherapy 2Ipilimumab 2Immunotherapy 2Gemcitabine 2Filgrastim 2Cisplatin 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Ipilimumab × Dermatologic × Clear all
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma AS

Phase 1 Completed
80 enrolled
BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡